Çocukta tromboz: Kime, hangi test, ne zaman, ne kadar gerekli?

CELKAN, Tülin Tiraje; DİKME, Gürcan

doi:10.5152/TurkPediatriArs.2018.2586

Çocukta tromboz: Kime, hangi test, ne zaman, ne kadar gerekli?

Tülin Tiraje CELKAN, (İstanbul Üniversitesi, Cerrahpaşa Tıp Fakültesi, Çocuk Sağlığı ve Hastalıkları Anabilim Dalı, Hematoloji-Onkoloji Bilim Dalı, İstanbul, Türkiye)

Gürcan Dikme (İstanbul Üniversitesi, Cerrahpaşa Tıp Fakültesi, Çocuk Sağlığı ve Hastalıkları Anabilim Dalı, Hematoloji-Onkoloji Bilim Dalı, İstanbul, Türkiye)

Türk Pediatri Arşivi

7 1

Yıl: 2018 Cilt: 53 Sayı: 1 Sayfa Aralığı: 1 - 9 Metin Dili: Türkçe DOI: 10.5152/TurkPediatriArs.2018.2586 İndeks Tarihi: 16-06-2020

Çocukta tromboz: Kime, hangi test, ne zaman, ne kadar gerekli?

Öz:

Çocukluk çağı trombozunda kalıtsal ve edinsel birçok risk etkenirol oynar. İki binli yıllardan sonra çocukluk çağı trombozu ile ilişkili birçok derleme ve meta-analizde, kalıtsal trombofili risk etkenitaşıyan çocuklarda artmış tromboz riskinden söz edilmektedir. Buderlemede yeni yayınlar ışığında, farklı hastalık gruplarında tromboz ve trombofili incelemesinin gerekliliği ve getirisinden bahsedilecektir

Anahtar Kelime:

Thrombosis in children: Which test to whom, when and how much necessary?

Öz:

Pediatric thrombosis is multifactorial, and usually risk factors either congenital or acquired are present. After 2000, systematic reviews and meta-analysis on pediatric venous thromboembolic disease and inherited thrombophilia revealed elevated thrombotic risks in these children. In this review, we discuss thrombosis and new literature in various pediatric patient groups and the usefulness of thrombophilia testing.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık

1. Gürgey A. Tromboz. Katkı Dergisi 2001; 22: 170-217.
2. Celkan T. Çocukluk çağında kalıtsal nedenli tromboz. Türk Pediatri Arşivi 2003; 3: 131-46.
3. Yang JY, Chan AK. Pediatric thrombophilia. Pediatr Clin North Am 2013; 60: 1443-62. [CrossRef ]
4. Raffini L. Thrombophilia in children: who to test, how, when, and why? Hematology Am Soc Hematol Educ Program 2008: 228-35. [CrossRef ]
5. Van Ommen CH, Middeldorp S. Thrombophilia in childhood: to test or not to test? Semin Thromb Hemost 2011; 37: 794-801. [CrossRef ]
6. Tormene D, Gavossos S, Rosette V, Simioni P. Thrombosis and thrombophilia in children. Semin Thromb Hemost 2006; 32: 724-8. [CrossRef ]
7. Andrew M, David M, Adams M, et al. Venous thromboembolic complications (VTE) in children: first analyses of the Canadian Registry of VTE. Blood 1994; 83: 1251-7.
8. De Stefano V, Rossi E. Testing for inherited thrombophilia and consequences for antithrombotic prophylaxis in patients with venous thromboembolism and their relatives. A review of the Guidelines from Scientific Societies and Working Groups. Thromb Haemost 2013; 110: 697-705. [CrossRef]
9. Klaassen ILM, van Ommen H, Middeltorp S. Manifestations and clinical impact of pediatric inherited thrombophilia. Blood 2015; 125: 1073-7. [CrossRef ]
10. Tormene D, Simioni P, Prandoni P, et al. The incidence of venous thromboembolismin thrombophilic children: a prospective cohort study. Blood 2002; 100: 2403–5. [CrossRef ]
11. Franchini M, Martinelli I, Mannucci PM. Uncertain thrombophilia markers. Thromb Haemost 2016; 115: 25- 30. [CrossRef ]
12. Middeldorp S. Inherited thrombophilia: a double-edged sword. Hematology Am Soc Hematol Educ Program 2016; 2016: 1-9. [CrossRef ]
13. Baglin T, Gray E, Greaves M, et al. British Committee for Standards in Haematology. Clinical guidelines for testing for heritable thrombophilia. Br J Haematol 2010; 149: 209-20. [CrossRef ]
14. Middeldorp S, van Hylckama Vlieg A. Does thrombophilia testing help in the clinical management of patients? Br J Haematol 2008; 143: 321-35. [CrossRef ]
15. Pernod G, Biron-Andreani C, Morange PE, et al. French Group on Haemostasis and Thrombosis; French Society of Vascular Medicine. Recommendations on testing for thrombophilia in venous thromboembolic disease: a French consensus guideline. J Mal Vasc 2009; 34: 156- 203. [CrossRef ]
16. Favaloro EJ, Bonar R, Kershaw G, Duncan E, Sioufi J, Marsden K. Investigations from external quality assurance programs reveal a high degree of variation in the laboratory identification of coagulation factor inhibitors. Semin Thromb Hemost 2009; 35: 794-805. [CrossRef ]
17. Tormene D, Pagnan A, Prandoni P, Simioni P. Screening for thrombophilia in children: a puzzling decision with unclear implications. J Thromb Haemost 2004; 2: 1193- 4. [CrossRef ]
18. Ehrenforth S, Junker R, Koch HG, et al. Multicenter evaluation of combined prothrombotic defects associated with thrombophilia in childhood. Eur J Pediatr 1999; 158: 97-104. [CrossRef ]
19. Vossen CY, Conard J, Fontcuberta J, et al. Risk of a first venous thrombotic event in carriers of a familial thrombophilic defect. The European Prospective Cohort on Thrombophilia (EPCOT). J Thromb Haemost 2005; 3: 459-64. [CrossRef ]
20. Revel-Vilk, A.Chan, M.Bauman, P.Massicotte. Prothrombotic conditions in an unselected cohort of children with venous thromboembolic disease. J Thromb Haemost 2003;1: 915-21. [CrossRef ]
21. Palareti G, Legnani C, Cosmi B, et al. Predictive value of D-dimer test for recurrent venous thromboembolism after anticoagulation withdrawal in subjects with a previous idiopathic event and in carriers of congenital thrombophilia. Circulation 2003; 108: 313-8. [CrossRef ]
22. Young G, Manco-Johnson M, Gill JC, et al. Clinical manifestations of the prothrombin G20210A mutation in children: a paediatric coagulation consortium study. J Thromb Haemost 2003; 1: 958-62. [CrossRef ]
23. Thom K, Male C, Mannhalter C, et al. No impact of endogenous prothrombotic conditions on the risk of central venous line-relatedthrombotic events in children: results of the KIDCAT study (KIDs with Catheter AssociatedThrombosis). J Thromb Haemost 2014; 12: 1610-5. [CrossRef ]
24. Simone B, De Stefano V, Leoncini E. Risk of venous thromboembolism associated with single and combined effects of factor V Leiden, prothrombin 20210A and methylenetethraydrofolate reductase C677T: a metaanalysis involving over 11,000 cases and 21,000 controls. Eur J Epidemiol 2013; 28: 621-47. [CrossRef ]
25. Prandoni P, Noventa F, Ghirarduzzi A, et al. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. Haematologica 2007; 92: 199-205. [CrossRef ]
26. Baglin T, Luddington R, Brown K, et al. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. Lancet 2003; 362: 523-6. [CrossRef ]
27. Simioni P. Risk of recurrent venous thromboembolism and thrombophilia: does discrepancy make complexity or vice versa ? J Thromb Haemost 2003; 1: 16-18. [CrossRef ]
28. Tosetto A, Iorio A, Marcucci M, et al. Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: a proposed prediction score (DASH). J Thromb Haemost 2012; 10: 1019-25. [CrossRef ]
29. Cohn DM, Vansenne F, de Borgie CA, et al. Thrombophilia testing for prevention of recurrent venous thromboembolism. Cochrane Database Syst Rev 2012; 12: CD007069. [CrossRef ]
30. Kearon C, Akl EA, Comerota AJ, et al. American College of Chest Physicians. Antithrombotic therapy for VTE disease: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence Based Clinical Practice Guidelines. Chest 2012; 141: e419S-94S.
31. Lijfering WM, Brouwer JL, Veeger NJ, et al. Selective testing for thrombophilia in patients with first venous thrombosis: results from a retrospective family cohort study on absolute thrombotic risk for currently known thrombophilic defects in 2479 relatives. Blood 2009; 113: 5314-22. [CrossRef ]
32. Carraro P; European Communities Confederation of Clinical Chemistry and Laboratory Medicine, Working Group on Guidelines for Investigation of Disease. Guidelines for the laboratory investigation of inherited thrombophilias. Recommendations for the first level clinical laboratories. Clin Chem Lab Med 2003; 41: 382-91. [CrossRef ]
33. Lussana F, Dentali F, Abbate R, et al. Italian Society for Haemostasis and Thrombosis. Screening for thrombophilia and antithrombotic prophylaxis in pregnancy: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET). Thromb Res 2009; 124: e19-25. [CrossRef ]
34. Mitchell LG, Andrew M, Hanna K, et al. A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L-asparaginase: results of the Prophylactic Antithrombin Replacement in Kids with Acute Lymphoblastic Leukemia Treated with Asparaginase (PARKAA) Study. Cancer 2003; 97: 508-16. [CrossRef ]
35. Albisetti M, Kellenberger CJ, Bergsträsser E, et al. Port-acath-related thrombosis and postthrombotic syndrome in pediatric oncology patients. J Pediatr 2013; 163: 1340- 6. [CrossRef ]
36. Hanmod SS, Jesudas R, Kulkarni R, Chitlur M. Neonatal hemostatic disorders: issues and challenges. Semin Thromb Hemost 2016; 42: 741-51. [CrossRef ]
37. Park CK, Paes BA, Nagel K, et al. Neonatal central venous catheter thrombosis: diagnosis, management, and outcome. Blood Coagul Fibrinolysis. 2016 Jul 29. [Epub ahead of print] 38. Saracco P, Bagna R, Gentilomo C, et al. Neonatal Working Group of Registro Italiano Trombosi Infantili (RITI). Clinical Data of Neonatal Systemic Thrombosis. J Pediatr 2016; 171: 60–6.e1. [CrossRef ]
39. Berfelo FJ, Kersbergen KJ, van Ommen CH, et al. Neonatal cerebral sinovenous thrombosis from symptom to outcome. Stroke 2010; 41: 1382-8. [CrossRef ]
40. Michot C, Garnier A, Neve M, Naudin J, Tsapis M, Dauger S. Neonatal renal venous thrombosis: the recent experience of Robert-Debré Hospital. Arch Pediatr 2011; 18: 1055-61. [CrossRef ]
41. Resontoc LP, Yap HK. Renal vascular thrombosis in the newborn. Pediatr Nephrol 2016; 31: 907-15. [CrossRef ]
42. Alioglu B, Avci Z, Tokel K, Atac FB, Ozbek N. Thrombosis in children with cardiac pathology: analysis of acquired and inherited risk factors. Blood Coagul Fibrinolysis 2008; 19: 294-304. [CrossRef ]
43. Kerlin BA, Ayoob R, Smoyer WE; Epidemiology and pathophysiology of nephrotic syndrome–associated thromboembolic disease. clin j am soc nephrol 2012; 7: 513-20 [CrossRef ]
44. Eltayeb AA, Askar GA, Abu Faddan NH, Kamal TM. Prothrombotic risk factors and antithrombotic therapy in children with ischemic stroke. Ther Adv Neurol Disord 2015; 8: 71-81. [CrossRef ]
45. Nowak-Gottl U, Strater R, Heinecke A, et al. Lipoprotein (a) and genetic polymorphism of clotting factor V, prothrombin, and methylenetetrahydrofolate reductase are risk factors of spontaneous ischemic stroke in childhood. Blood 1999; 94: 3678-82.
46. O’Brien SH, Smith KJ. Using thrombophilia testing to determine anticoagulation duration in pediatric thrombosis is not cost-effective. J Pediatr 2009; 155: 100-4. [CrossRef ]
47. De Stefano V, Simioni P, Rossi E, et al. The risk of recurrent venous thromboembolism in patients with inherited deficiency of natural anticoagulants antithrombin, protein C, and protein S. Haematologica 2006; 91: 695-8.
48. Vossen CY, Walker ID, Svensson P, et al. Recurrence rate after a first venous thrombosis in patients with familial thrombophilia. Arterioscler Thromb Vasc Biol 2005; 25: 1992-7. [CrossRef ]
49. Nowak-Gottl U, Junker R, Kreuz W, et al. Childhood Thrombophilia Study Group. Risk of recurrent venous thrombosis in children with combined prothrombotic risk factors. Blood 2001; 97: 858-62. [CrossRef ]
50. Cohn DM, Vansenne F, Kaptein AA, De Borgie CA, Middeldorp S. The psychological impact of testing for thrombophilia: a systematic review. J Thromb Haemost 2008; 6: 1099-104. [CrossRef ]

APA	CELKAN T, DİKME G (2018). Çocukta tromboz: Kime, hangi test, ne zaman, ne kadar gerekli?. , 1 - 9. 10.5152/TurkPediatriArs.2018.2586
Chicago	CELKAN Tülin Tiraje,DİKME Gürcan Çocukta tromboz: Kime, hangi test, ne zaman, ne kadar gerekli?. (2018): 1 - 9. 10.5152/TurkPediatriArs.2018.2586
MLA	CELKAN Tülin Tiraje,DİKME Gürcan Çocukta tromboz: Kime, hangi test, ne zaman, ne kadar gerekli?. , 2018, ss.1 - 9. 10.5152/TurkPediatriArs.2018.2586
AMA	CELKAN T,DİKME G Çocukta tromboz: Kime, hangi test, ne zaman, ne kadar gerekli?. . 2018; 1 - 9. 10.5152/TurkPediatriArs.2018.2586
Vancouver	CELKAN T,DİKME G Çocukta tromboz: Kime, hangi test, ne zaman, ne kadar gerekli?. . 2018; 1 - 9. 10.5152/TurkPediatriArs.2018.2586
IEEE	CELKAN T,DİKME G "Çocukta tromboz: Kime, hangi test, ne zaman, ne kadar gerekli?." , ss.1 - 9, 2018. 10.5152/TurkPediatriArs.2018.2586
ISNAD	CELKAN, Tülin Tiraje - DİKME, Gürcan. "Çocukta tromboz: Kime, hangi test, ne zaman, ne kadar gerekli?". (2018), 1-9. https://doi.org/10.5152/TurkPediatriArs.2018.2586

APA	CELKAN T, DİKME G (2018). Çocukta tromboz: Kime, hangi test, ne zaman, ne kadar gerekli?. Türk Pediatri Arşivi, 53(1), 1 - 9. 10.5152/TurkPediatriArs.2018.2586
Chicago	CELKAN Tülin Tiraje,DİKME Gürcan Çocukta tromboz: Kime, hangi test, ne zaman, ne kadar gerekli?. Türk Pediatri Arşivi 53, no.1 (2018): 1 - 9. 10.5152/TurkPediatriArs.2018.2586
MLA	CELKAN Tülin Tiraje,DİKME Gürcan Çocukta tromboz: Kime, hangi test, ne zaman, ne kadar gerekli?. Türk Pediatri Arşivi, vol.53, no.1, 2018, ss.1 - 9. 10.5152/TurkPediatriArs.2018.2586
AMA	CELKAN T,DİKME G Çocukta tromboz: Kime, hangi test, ne zaman, ne kadar gerekli?. Türk Pediatri Arşivi. 2018; 53(1): 1 - 9. 10.5152/TurkPediatriArs.2018.2586
Vancouver	CELKAN T,DİKME G Çocukta tromboz: Kime, hangi test, ne zaman, ne kadar gerekli?. Türk Pediatri Arşivi. 2018; 53(1): 1 - 9. 10.5152/TurkPediatriArs.2018.2586
IEEE	CELKAN T,DİKME G "Çocukta tromboz: Kime, hangi test, ne zaman, ne kadar gerekli?." Türk Pediatri Arşivi, 53, ss.1 - 9, 2018. 10.5152/TurkPediatriArs.2018.2586
ISNAD	CELKAN, Tülin Tiraje - DİKME, Gürcan. "Çocukta tromboz: Kime, hangi test, ne zaman, ne kadar gerekli?". Türk Pediatri Arşivi 53/1 (2018), 1-9. https://doi.org/10.5152/TurkPediatriArs.2018.2586